Derek J. Jonker

13.5k total citations · 4 hit papers
218 papers, 8.7k citations indexed

About

Derek J. Jonker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Derek J. Jonker has authored 218 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 173 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 48 papers in Cancer Research. Recurrent topics in Derek J. Jonker's work include Colorectal Cancer Treatments and Studies (118 papers), Gastric Cancer Management and Outcomes (43 papers) and Cancer Treatment and Pharmacology (43 papers). Derek J. Jonker is often cited by papers focused on Colorectal Cancer Treatments and Studies (118 papers), Gastric Cancer Management and Outcomes (43 papers) and Cancer Treatment and Pharmacology (43 papers). Derek J. Jonker collaborates with scholars based in Canada, United States and Australia. Derek J. Jonker's co-authors include Dongsheng Tu, Christos S. Karapetis, John Zalcberg, Chris J. O’Callaghan, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, R. J. Simes, Christiane Langer and Shirin Khambata‐Ford and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Derek J. Jonker

205 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. profile →
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

2013 438 citations Derek J. Jonker et al. profile →

Peers

Countries citing papers authored by Derek J. Jonker

Since Specialization

Citations

This map shows the geographic impact of Derek J. Jonker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek J. Jonker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek J. Jonker more than expected).

Fields of papers citing papers by Derek J. Jonker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek J. Jonker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek J. Jonker. The network helps show where Derek J. Jonker may publish in the future.

Co-authorship network of co-authors of Derek J. Jonker

This figure shows the co-authorship network connecting the top 25 collaborators of Derek J. Jonker. A scholar is included among the top collaborators of Derek J. Jonker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek J. Jonker. Derek J. Jonker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors 2024 ·Cancer Research Communications ·(unknown), (unknown), Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard J. Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, Stephen Chia, Hagen F. Kennecke, Derek J. Jonker, Eric X. Chen, Daniel J. Renouf, Chris J. O’Callaghan, Jonathan M. Loree	2
2	Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials 2024 ·Clinical Cancer Research ·(unknown), (unknown), Emma Titmuss, Dongsheng Tu, Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian L. Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O’Callaghan, Jonathan M. Loree	3
3	Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial 2024 ·Clinical Cancer Research ·Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly C. Banks, Katie Quinn, Aly Karsan, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen	11
4	The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17 2024 ·JNCI Journal of the National Cancer Institute ·Arjun Gupta, Christopher J. O’Callaghan, Liting Zhu, Derek J. Jonker, Ralph Wong, Bruce Colwell, Malcolm J. Moore, Christos S. Karapetis, Niall C. Tebbutt, Jeremy Shapiro, Dongsheng Tu, Christopher M. Booth	7
5	Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer 2023 ·Clinical Colorectal Cancer ·Di Jiang, (unknown), (unknown), Hao‐Wen Sim, Lillian L. Siu, Geoffrey Liu, Jeremy Shapiro, Timothy Price, Derek J. Jonker, Christos S. Karapetis, Andrew Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe Sabesan, Jenny Shannon, Amanda Townsend, Chris J. O’Callaghan, Eric X. Chen	0
6	A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial 2023 ·Cancer Research Communications ·Josep Tabernero, Takayuki Yoshino, Sebastian Stintzing, Aimery de Gramont, Peter Gibbs, Derek J. Jonker, Peter Nygren, Christos Papadimitriou, Gerald W. Prager, Roger Tell, Heinz‐Josef Lenz	5
7	A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes 2023 ·Statistics in Medicine ·Yangqing Deng, Dongsheng Tu, Chris J. O’Callaghan, Derek J. Jonker, Christos S. Karapetis, Jeremy Shapiro, Geoffrey Liu, Wei Xu	1
8	Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer 2023 ·Cancer Medicine ·(unknown), Karen Kopciuk, Hans J. Vogel, Patricia A. Tang, Jeremy Shapiro, Dongsheng Tu, Derek J. Jonker, Lillian L. Siu, Chris J. O’Callaghan, Oliver F. Bathe	5
9	Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial. 2023 ·Journal of Clinical Oncology ·Jonathan M. Loree, Russell W. Madison, Christopher J. O’Callaghan, Carl J. Brown, Dongsheng Tu, Derek J. Jonker, (unknown), Alexander D. Fine, Yanmei Huang, (unknown), Prapti Pokharel, Alexey Aleshin, Geoffrey R. Oxnard, Hagen F. Kennecke	0
10	Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials. 2023 ·Journal of Clinical Oncology ·(unknown), Nan Chen, Dongsheng Tu, Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian L. Siu, Jeremy Shapiro, John Simes, Christopher J. O’Callaghan, Jonathan M. Loree	1
11	Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results 2022 ·Journal of Clinical Oncology ·Hagen F. Kennecke, Chris J. O’Callaghan, Jonathan M. Loree, (unknown), Rebecca C. Auer, Derek J. Jonker, Manoj J. Raval, Reilly Musselman, (unknown), Antonio Caycedo‐Marulanda, Vlad V. Simianu, Sunil V. Patel, (unknown), Ramzi M. Helewa, Vallerie Gordon, (unknown), Halla Nimeiri, (unknown), Dongsheng Tu, Carl J. Brown	31
12	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 2021 ·Cancers ·Elena De Mattia, Jerry Polesel, Rossana Roncato, (unknown), Alessia Bignucolo, Sara Gagno, Angela Buonadonna, Mario D’Andrea, Éric Lévesque, Derek J. Jonker, Félix Couture, Chantal Guillemette, Erika Cecchin, Giuseppe Toffoli	8
13	Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial 2020 ·Clinical Cancer Research ·Jonathan M. Loree, (unknown), Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O’Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz	19
14	Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer 2018 ·Cancer Medicine ·Daniel Shepshelovich, Amanda Townsend, Osvaldo Espin‐Garcia, Lidija Latifovic, Chris J. O’Callaghan, Derek J. Jonker, Dongsheng Tu, Eric X. Chen, Eric Morgen, Timothy Price, Jeremy Shapiro, Lillian L. Siu, Michiaki Kubo, Alexander Dobrovic, Mark J. Ratain, Wei Xu, Taisei Mushiroda, Geoffrey Liu	20
15	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis 2017 ·BMJ Open ·Emma Grigor, Dean Fergusson, Fatima Haggar, Natasha Kekre, Harold Atkins, Risa Shorr, Robert A. Holt, Brian Hutton, Tim Ramsay, Matthew D. Seftel, Derek J. Jonker, Mads Daugaard, Kednapa Thavorn, Justin Presseau, Manoj M. Lalu	20
16	Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid 2016 ·Clinical Colorectal Cancer ·Michael Yan, Cheryl Ho, Eric Winquist, Derek J. Jonker, Daniel Rayson, Larry Stitt, Sonya Tokmakejian, Anna Tomiak, Mark Vincent	7
17	A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial 2016 ·Annals of Oncology ·Derek J. Jonker, Louise Nott, Takayuki Yoshino, Satinder Gill, Jeremy Shapiro, Atsushi Ohtsu, John Zalcberg, Michael M. Vickers, Alice C. Wei, Yuan Gao, Niall C. Tebbutt, Ben Markman, Taito Esaki, Sheryl Koski, Matthew Hitron, Nadine M Magoski, John Simes, (unknown), Dongsheng Tu, Chris J. O’Callaghan	13
18	A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers 2014 ·Clinical Cancer Research ·Ulrik Lassen, Didier Meulendijks, L.L. Siu, Vaios Karanikas, Morten Mau‐Sørensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary Ellen Simcox, Kathleen Schostack, Dean Bottino, Hua Zhong, Markus Roeßler, (unknown), (unknown), David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss	32
19	Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease 2011 ·Clinical & Experimental Metastasis ·Michael M. Vickers, Jair Bar, (unknown), Nirit Yarom, Manijeh Daneshmand, Jennifer Hanson, Christina Addison, Timothy R. Asmis, Derek J. Jonker, Jean A. Maroun, Ian Lorimer, Glenwood D. Goss, Jim Dimitroulakos	99
20	ASSOCIATIONS BETWEEN GERMLINE GENOTYPE AND EFFICACY AND SAFETY OUTCOMES IN A PHASE III STUDY OF SUNITINIB AND FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC) 2011 ·Annals of Oncology ·Eric Van Cutsem, Feng Gao, (unknown), James A. Williams, Xun Lin, Derek J. Jonker, Yan Sun, Jhony A. De La Cruz‐Vargas, Jennifer Tursi, María José Lechuga, Alfredo Carrato	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact